Ireland must brace for FDI slowdown, boost local champions
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email In just 50 years, Ireland…
ADHD medication in short supply in Japan as demand soars
Since last fall, Concerta, a medication used for the treatment of attention deficit hyperactivity disorder (ADHD), has been…
Eli Lilly reaches deal to bring AI-developed drugs to global market
A drone view shows the Eli Lilly logo on the company’s office in San Diego, California, Nov. 21,…
White House shares legislative text of MFN drug bill with drugmakers
WASHINGTON — The White House has drafted legislative text for its drug pricing policy, and officials are in…
Pfizer Lyme disease vaccine fails trial, company to seek FDA approval
Thomas Fuller | Nurphoto | Getty Images Pfizer on Monday said it will seek regulatory approval for a…
Eli Lilly’s obesity drug retatrutide clears late-stage diabetes trial
The Eli Lilly logo appears on the company’s office in San Diego, California, U.S., Nov. 21, 2025. Mike…
Trump gets more credit than Biden for trying to lower drug prices
WASHINGTON — Reining in drug prices has been a priority for both the Trump and Biden administrations. Trump…
Breakout Ventures eyes neuroscience and AI with new fund
Investment firm Breakout Ventures has $114 million in new venture capital funds that it expects to put…
Trump angering MAHA with glyphosate order gives Democrats an opening
An attendee holds a Make America Healthy Again (MAHA) Moms sign at the end of a press conference…
Health Headlines: From Cyprus Livestock Controls to Novo’s Market Shakeup
Health news this week is dominated by significant developments affecting the global landscape. Cyprus has implemented strict…
Hims & Hers Health addresses scrutiny of GLP-1 compounding| STAT
Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the…
Pharma companies turn to Trump-connected firms for FDA lobbying
Pharmaceutical giants, seeing a wave of new risks and potential rewards in President Trump’s second term, are boosting…